NVTA News and Press, Invitae Corporation From 02/27/23

Invitae ( NYSE: NVTA ) is scheduled to announce Q4 earnings results on Tuesday, February 28th, after market close. The consensus EPS Estimate is -$0.53 (+34.6% Y/Y) and the consensus Revenue Estimate is $120.98M (-4.1% Y/Y). Over the last 2 years, NVTA has beaten EPS estimat...

With shares down by 91% in the last three years, and 78% in the last 12 months alone, Invitae (NYSE: NVTA) and its investors are bound to be feeling the burn. The genetic testing company's downward spiral led Wall Street analysts to downgrade the stock, and many are suggesting that shareh...

Genetic testing company Invitae (NYSE: NVTA) has a lot of long-term potential as it could help improve the quality of healthcare for people and play a big role in transforming the industry. It has an ambitious goal of making genetic testing more efficient and affordable. But it's an uphil...

Invitae to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023 PR Newswire SAN FRANCISCO , Feb. 14, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourt...

Invitae (NYSE: NVTA) is a promising business specializing in genetic testing, which could be the wave of the future in healthcare. Genetic tests can uncover mutations or variants in your DNA, which can help prevent illnesses and treat them more effectively. But while it's a good opportu...

Shares of genetic testing company Invitae (NYSE: NVTA) have surged more than 40% over the past month, a combination of improving investor sentiment toward growth stocks as well as the company's preliminary release of financial results for 2022. The company has seemingly made considerable ...

Call them “ penny stocks ” or simply call them cheap stocks under $5; there’s something to be said about trading low-priced equities. The only problem is that if you’re new to trading, you might be limited in which stocks under $5 you can buy and sell. For this...

The shares of Invitae Corporation ( NYSE: NVTA ) fell ~5% pre-market Tuesday after Goldman Sachs downgraded it to Sell from Neutral predicting a long path to profitability for the medical diagnostics company despite its recent efforts at restricting. While the company’s...

Summary BNGO reported preliminary Q4 results, showing acceptable core business performance. Aggressive expansion into capital-intensive markets could put significant pressure on BNGO's balance sheet. Recently-introduced LDTs will likely have a limited impact on revenue growth. ...

Invitae Appoints William H. Osborne to its Board of Directors PR Newswire – Brings invaluable expertise in leading, operating and scaling global businesses throughout his career in aerospace, transportation and integrated solutions – SAN FRANCISCO , ...